Utikal Jochen, Schadendorf Dirk, Ugurel Selma
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany.
Arch Dermatol Res. 2007 Mar;298(10):469-77. doi: 10.1007/s00403-006-0726-5.
Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
生物标志物是各种皮肤恶性肿瘤临床诊断和预后分类的重要工具。除了临床和组织病理学方面(例如原发肿瘤的解剖部位和类型、肿瘤大小和浸润深度、溃疡、血管浸润),越来越多的分子标志物已被鉴定出来,这为肿瘤实体进行更详细的诊断和预后亚组划分提供了可能,甚至可能改变现有的分类系统。最近发表的基因表达或蛋白质组学分析数据涉及参与皮肤癌发病机制的新标志物分子,经过适当研究验证后,这些分子可能代表皮肤恶性肿瘤未来的预后或预测生物标志物。在此,我们概述了最常见的皮肤恶性肿瘤、恶性黑色素瘤、鳞状细胞癌和皮肤淋巴瘤中目前已知的血清学和更新的免疫组化生物标志物分子,特别强调它们的预后和预测意义。